Featured Tickers:
Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Viridian Therapeutics, Inc., Kymera Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Viridian Therapeutics, Inc., Kymera Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.
About Viridian Therapeutics, Inc., Kymera Therapeutics and Inc.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company’s product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Latest Biotechnology and Viridian Therapeutics, Inc., Kymera Therapeutics, Inc. Stock News
As of November 6, 2025, Viridian Therapeutics, Inc. had a $2.6 billion market capitalization, compared to the Biotechnology median of $203.9 million. Viridian Therapeutics, Inc.’s stock is up 38.6% in 2025, up 12.5% in the previous five trading days and up 20.4% in the past year.
Currently, Viridian Therapeutics, Inc. does not have a price-earnings ratio. Viridian Therapeutics, Inc.’s trailing 12-month revenue is $70.8 million with a -426.6% net profit margin. As of November 6, 2025, Viridian Therapeutics, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.152 per share for the current fiscal year. Viridian Therapeutics, Inc. does not currently pay a dividend.
As of November 6, 2025, Kymera Therapeutics, Inc. had a $4.4 billion market cap, putting it in the 67th percentile of all stocks. Kymera Therapeutics, Inc.’s stock is up 42% in 2025, down 7.6% in the previous five trading days and up 29.59% in the past year.
Currently, Kymera Therapeutics, Inc. does not have a price-earnings ratio. Kymera Therapeutics, Inc.’s trailing 12-month revenue is $43.7 million with a -674.8% net profit margin. Year-over-year quarterly sales growth most recently was -24.3%. Analysts expect adjusted earnings to reach $-3.496 per share for the current fiscal year. Kymera Therapeutics, Inc. does not currently pay a dividend.
How We Compare Viridian Therapeutics, Inc., Kymera Therapeutics and Inc. Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Viridian Therapeutics, Inc., Kymera Therapeutics and Inc.’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions